Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Trial Profile

A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Prednisolone acetate
  • Indications Uveitis
  • Focus Registrational; Therapeutic Use
  • Sponsors EyeGate Pharma
  • Most Recent Events

    • 04 Sep 2018 According to EyeGate Pharma media release, company announced top-line results from this trial.
    • 04 Sep 2018 Results published in the EyeGate Pharma Media Release
    • 04 May 2015 The US FDA provided guidance that if a confirmatory phase III trial of EGP-437 in anterior uveitis ((see trial profile 700255415) meets non-inferiority criteria, data from that trial along with data from this trial will be sufficient to support a New Drug Application (NDA) filing, according to an EyeGate Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top